抗IgE靶向治疗中重度过敏性哮喘的研究进展

Research progress of anti IgE targeted therapy for moderate and severe allergic asthma

过敏性支气管哮喘是一种常见的慢性气道炎症性疾病,在过敏原的刺激下反复发作和逐渐进展。当发展成中重度过敏性哮喘时,中高剂量的糖皮质激素联合长效β_(2)受体激动剂等均难以控制。奥马珠单抗作为一种新型的重组人源化抗IgE抗体,在中重度过敏性哮喘的靶向治疗中发挥着重要的作用。文章就奥马珠单抗治疗中重度过敏性哮喘的疗效、不良反应、停药时间探究及新型冠状病毒肺炎形式下的治疗策略进行综述。

Allergic bronchial asthma is a common chronic inflammatory disease of the airway,which occurs repeatedly and progresses gradually under the stimulation of allergens.When the development of moderate or severe allergic asthma,medium and high doses of glucocorticoids combined with long-acting β_(2) agonists are difficult to control.Omalizumab,as a novel recombinant humanized antilgE antibody,plays an important role in the targeted therapy of moderate and severe allergic asthma.This article reviews the efficacy,adverse reactions,withdrawal time of omalizumab in the treatment of moderate and severe allergic asthma,and the treatment strategies in the form of COVID-19.